Welcome to our dedicated page for CLABD news (Ticker: CLABD), a resource for investors and traders seeking the latest updates and insights on CLABD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CLABD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CLABD's position in the market.
Core One Labs Inc. (CSE: COOL, OTC: CLABD) announced that Dr. Robert E.W. Hancock, Chairman and CEO of Vocan Biotechnologies, will present at a Virtual Town Hall on August 4, 2021, at 1:30 p.m. PST. The presentation will cover the Company’s proprietary biosynthesized psilocybin, its collaboration with the University of British Columbia, and ongoing patent processes. Investors can participate live or view the recording later. Core One is focused on delivering psychedelic medications through innovative systems aimed at mental health treatments.
Core One Labs Inc. (CSE: COOL, OTC: CLABD) announced that its subsidiary, Akome Biotech Ltd., has initiated the development of a new psychedelic drug formulation, AKO004, aimed at treating Parkinson's disease. The company has filed a provisional patent application with the USPTO to protect its intellectual property. Initial analyses indicate that AKO004, which combines DMT with a natural plant bioactive, demonstrates safety and efficacy, with properties that may help mitigate neurodegeneration. This announcement underscores Core One's commitment to innovative treatments for neurodegenerative conditions.
Core One Labs Inc. (OTC: CLABD) announces significant progress with its subsidiary Akome Biotech, focusing on a patented ketamine formulation, AKO003, targeting depression treatment. A provisional patent application has been filed, marking a pivotal step towards human trials. This formulation combines ketamine with a proprietary plant bioactive, aiming to enhance efficacy while reducing side effects. With approximately 33% of patients unresponsive to traditional antidepressants, Akome's innovation positions the company as a leader in the evolving mental health treatment market.
Core One Labs Inc. has announced a Letter of Intent (LOI) to acquire Vocan Biotechnologies Inc., effective October 1, 2020. Vocan specializes in psilocybin production through a proprietary fermentation system, aiming to enhance access to this compound for mental health treatment. The acquisition involves issuing 23.5 million common shares and 4 million warrants. Vocan’s experienced leadership includes Dr. Robert Hancock and Dr. Jan Burian. The deal requires due diligence and regulatory approvals but is expected to bolster Core One’s position in the psychedelics market.
Core One Labs Inc. has received a revocation of the cease trade order from the British Columbia Securities Commission effective August 26, 2020. This comes after the company filed necessary financial statements, ensuring compliance with continuous disclosure obligations. However, delays in filing interim financial statements for the period ending June 30, 2020, are expected due to the COVID-19 pandemic, with estimates indicating submission by October 14, 2020. The company continues to uphold an insider trading blackout until the interim filings are complete.
